Understanding Mantle Cell Lymphoma: A Patient's Guide
Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin lymphoma (NHL) that develops in the outer edge, or “mantle zone,” of a lymph node. It accounts for approximately 6% of all NHL cases in the United States, with roughly 4,000 new diagnoses each year.
What Makes MCL Different?
MCL is unique among lymphomas because it often behaves aggressively while also sharing some characteristics with slower-growing (indolent) lymphomas. This dual nature makes treatment decisions particularly important and underscores the value of working with specialists who have experience with this specific disease.
Key Facts About MCL
- Who is affected: MCL is most commonly diagnosed in adults over age 60, with a median age at diagnosis of 68. It affects men approximately three times more often than women.
- Diagnosis: MCL is typically diagnosed through a lymph node biopsy and confirmed by the presence of a specific genetic marker — the translocation t(11;14) — along with overexpression of the cyclin D1 protein.
- Staging: Like other lymphomas, MCL is staged from I to IV, with most patients diagnosed at stage III or IV.
Treatment Landscape
The treatment landscape for MCL has evolved significantly. Options now include chemotherapy, immunotherapy, targeted therapies (such as BTK inhibitors), and stem cell transplantation. The choice of treatment depends on several factors, including the patient’s age, overall health, and the specific characteristics of their disease.
The Importance of Expertise
Because MCL is rare, we strongly encourage patients to seek care from, or at minimum consult with, oncologists who have specific experience treating this disease. A specialist can help ensure you have access to the latest treatment options, including clinical trials.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.